Rexahn Pharmaceuticals, Inc. (REXN)

[surf1944]

8:01AM Rexahn Pharmaceuticals in-licenses novel oligonucleotide targeted drug delivery platform from Ohio State University (RNN) 0.52 : Co announced that it has signed an exclusive license agreement with the Ohio State Innovation Foundation, an affiliate of The Ohio State University, for a novel oligonucleotide drug delivery platform, Lipid-Coated Albumin Nanoparticle, developed at The Ohio State University College of Pharmacy. In preclinical studies, the LCAN platform has demonstrated the ability to deliver oligonucleotide compounds into cancer tumors, which can result in improved safety and efficacy. Rexahn's first preclinical candidate to be developed with this delivery platform will be RX-0201-nano.